Shield Therapeutics Achieves Positive Cash Flow in Q4 2025 and Forecasts Operating Profit for 2026

Shield Therapeutics Q4 2025 trading update: cash flow positive and operating profit targeted for 2026

Shield Therapeutics has ticked off a big milestone. The company delivered positive operating cash flow in Q4 2025 and expects to post an operating profit in 2026. The engine behind it is ACCRUFeR in the US, where both price and prescriptions moved higher in 2025.

This update is unaudited, but the direction of travel is clear – revenues up, costs under control, and a cleaner prescription mix. Below I break down the headline numbers and why they matter for retail holders.

Headline numbers at a glance

Metric	Update
Total Group revenues (FY25)	c. $50m (FY24: $32m revenues and other income)
ACCRUFeR revenues (FY25)	$46m, up 56% (FY24: $29m)
Average net selling price – ANSP (FY25)	$223, up 21%
Total ACCRUFeR prescriptions (FY25)	c. 199,000, up 33%
Q4 ACCRUFeR net revenues	$13.5m (Q4 2024: $11.2m)
Q4 ACCRUFeR prescriptions	c. 61,000 (Q4 2024: c. 41,000)
Q4 ANSP	$222 (Q4 2024: $237)
Q4 consignment-based prescriptions	c. 21% of dispenses (c. 22% in Q4 2024)
Cash and cash equivalents (31 Dec 2025)	$11.6m (30 Sep 2025: $8.6m)
Q4 operating cash flow	+$1m, excluding $1.96m net proceeds from amended Senior Secured Debt Financing

ACCRUFeR growth: price up 21% and scripts up 33% in 2025

ACCRUFeR drove the year, delivering $46m of revenue, up 56% year-on-year. That growth came from two levers: more prescriptions and a higher net price. Total prescriptions climbed c. 33% to c. 199,000, while the average net selling price increased 21% to $223.

This is exactly the kind of mix shareholders want to see. Volume proves demand, price proves payer traction, and together they compound. It also underpins the company’s confidence in reaching operating profitability in 2026.

Fourth-quarter dynamics: record scripts, lower net price

Q4 was the strongest quarter on dispenses since launch, with c. 61,000 prescriptions versus c. 41,000 a year earlier. Net revenues of $13.5m in Q4 were up from $11.2m in Q4 2024, reflecting the scale effects coming through the P&L.

One note of caution: Q4 ANSP dipped to $222 from $237 in Q4 2024. Management attributes this to an increase in covered rebated prescriptions compared to prior quarters. That’s a classic trade-off – better coverage and access often comes with higher rebates, which trims the net price. On balance it is still positive for market share, but investors should monitor the net price trend in 2026.

Encouragingly, consignment-based prescriptions – dispensed at a subsidised price and not reimbursed by payors – were c. 21% of dispenses in Q4 (c. 22% in Q4 2024). A lower reliance on consignment should support cash conversion as more volume moves into fully reimbursed channels.

Cash and balance sheet: positive operating cash flow and $11.6m cash

Cash and cash equivalents stood at $11.6m at 31 December 2025, up from $8.6m at 30 September 2025. Shield achieved positive operating cash flow of $1m in Q4, excluding $1.96m of net proceeds from an amended Senior Secured Debt Financing received in the quarter.

That operating cash flow inflection is important. As the CEO put it, reaching cash flow positivity is a milestone that supports growth without the need for further external financing. The company’s wider cash runway is not disclosed, but the combination of rising revenues, improving mix and positive operating cash flow is moving Shield in the right direction.

Outlook: operating profit expected in 2026

Shield states that it expects to deliver an operating profit in 2026. That would mark a key transition from cash burn to cash generation, driven by scaling ACCRUFeR in the US and disciplined cost and working capital management.

For valuation, shifting into operating profitability can be a catalyst – it reduces uncertainty around future funding and can broaden the investor base. Execution remains crucial, particularly sustaining script growth while protecting net pricing.

What it means for investors: positives and watch items

• Momentum intact – FY25 Group revenues of c. $50m and ACCRUFeR revenues up 56% to $46m show strong commercial traction.

• Unit economics improving – FY25 ANSP up 21% to $223 and total scripts up c. 33% underpin operating leverage.

• Cash conversion turning – positive Q4 operating cash flow and cash of $11.6m at year-end improve financial flexibility.

• Guidance signal – management expects an operating profit in 2026, a meaningful step change.

• Pricing mix to watch – Q4 ANSP of $222 was lower year-on-year due to more rebated coverage. Monitor net price in 2026.

• Consignment mix still present – c. 21% of Q4 dispenses were consignment-based. Further reductions would support margins and cash.

• Granularity – detailed FY25 P&L, cash burn by quarter, and 2026 guidance beyond operating profit are not disclosed.

ACCRUFeR and the market opportunity

ACCRUFeR/FeRACCRU (ferric maltol) is a novel, non-salt-based oral iron therapy for adults with iron deficiency, with or without anaemia. It is the first and only FDA-approved oral iron to treat ID/IDA, and has shown efficacy and good tolerability across multiple clinical trials.

Shield cites a US patient population of about 20 million and a $2.3 billion market opportunity for ID and IDA. ACCRUFeR is described as the leading #1 branded prescription oral iron in the market today for ID/IDA (data source – IQVIA Xponent PlanTrak).

Key catalyst: investor presentation

Management will host a live online presentation at 2:00 pm (GMT) on 22 January 2026 via the Investor Meet Company platform. You can register here:

Investor Meet Company – Shield Therapeutics

Bottom line: scaling up with a line of sight to profitability

Shield’s FY25 finish was solid: record quarterly dispenses, rising annual price and volume, and operating cash flow turning positive. The guidance for operating profit in 2026 raises the stakes for execution, but the commercial and financial trends are supportive.

If management can keep scripts growing while managing rebate pressure, and continue to lower the consignment mix, the step to sustainable profitability looks achievable. For now, this is a constructive update that should build confidence going into 2026.